221 related articles for article (PubMed ID: 21541781)
21. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers.
Weber C; Schmitt R; Birnboeck H; Hopfgartner G; Eggers H; Meyer J; van Marle S; Viischer HW; Jonkman JH
J Clin Pharmacol; 1999 Jul; 39(7):703-14. PubMed ID: 10392325
[TBL] [Abstract][Full Text] [Related]
22. Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Pulido T; Adzerikho I; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Jing ZC; Le Brun FO; Mehta S; Mittelholzer CM; Perchenet L; Sastry BK; Sitbon O; Souza R; Torbicki A; Zeng X; Rubin LJ; Simonneau G;
N Engl J Med; 2013 Aug; 369(9):809-18. PubMed ID: 23984728
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
[TBL] [Abstract][Full Text] [Related]
24. Lack of Pharmacokinetic Interactions Between Macitentan and a Combined Oral Contraceptive in Healthy Female Subjects.
Hurst N; Pellek M; Dingemanse J; Sidharta PN
J Clin Pharmacol; 2016 Jun; 56(6):669-74. PubMed ID: 26381054
[TBL] [Abstract][Full Text] [Related]
25. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
Dingemanse J; Sidharta PN; Maddrey WC; Rubin LJ; Mickail H
Expert Opin Drug Saf; 2014 Mar; 13(3):391-405. PubMed ID: 24261583
[TBL] [Abstract][Full Text] [Related]
26. The metabolism of the dual endothelin receptor antagonist macitentan in rat and dog.
Treiber A; Miraval T; Bolli MH; Funel JA; Segrestaa J; Seeland S
Xenobiotica; 2016; 46(3):253-67. PubMed ID: 26337830
[TBL] [Abstract][Full Text] [Related]
27. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension].
Avdeev SN
Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621
[TBL] [Abstract][Full Text] [Related]
28. Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model.
Hoenicka M; Golovchenko S; Englert L; Spaeth M; Shoshiashvili L; Großer C; Hofmann HS; Ried M
Cardiovasc Drugs Ther; 2019 Jun; 33(3):287-295. PubMed ID: 30826900
[TBL] [Abstract][Full Text] [Related]
29. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
Iglarz M; Bossu A; Wanner D; Bortolamiol C; Rey M; Hess P; Clozel M
Life Sci; 2014 Nov; 118(2):333-9. PubMed ID: 24582812
[TBL] [Abstract][Full Text] [Related]
30. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment.
Sidharta PN; Ulč I; Dingemanse J
Clin Drug Investig; 2019 Nov; 39(11):1117-1123. PubMed ID: 31435905
[TBL] [Abstract][Full Text] [Related]
31. Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro.
Weiss J; Theile D; Rüppell MA; Speck T; Spalwisz A; Haefeli WE
Eur J Pharmacol; 2013 Feb; 701(1-3):168-75. PubMed ID: 23353592
[TBL] [Abstract][Full Text] [Related]
32. Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects.
Fontes MSC; Dingemanse J; Sidharta PN
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):718-725. PubMed ID: 33063477
[TBL] [Abstract][Full Text] [Related]
33. Macitentan: A Review in Pulmonary Arterial Hypertension.
Keating GM
Am J Cardiovasc Drugs; 2016 Dec; 16(6):453-460. PubMed ID: 27580996
[TBL] [Abstract][Full Text] [Related]
34. Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials.
Khanna D; Denton CP; Merkel PA; Krieg T; Le Brun FO; Marr A; Papadakis K; Pope J; Matucci-Cerinic M; Furst DE; ;
JAMA; 2016 May; 315(18):1975-88. PubMed ID: 27163986
[TBL] [Abstract][Full Text] [Related]
35. Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.
de Kanter R; Sidharta PN; Delahaye S; Gnerre C; Segrestaa J; Buchmann S; Kohl C; Treiber A
Clin Pharmacokinet; 2016 Mar; 55(3):369-80. PubMed ID: 26385839
[TBL] [Abstract][Full Text] [Related]
36. Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.
Angus JA; Soeding PF; Hughes RJA; Wright CE
Eur J Pharmacol; 2017 Jun; 804():111-116. PubMed ID: 28300593
[TBL] [Abstract][Full Text] [Related]
37. The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross-species comparison of its cytochrome P450 induction pattern.
Treiber A; Delahaye S; Seeland S; Gnerre C
Pharmacol Res Perspect; 2020 Aug; 8(4):e00619. PubMed ID: 32613761
[TBL] [Abstract][Full Text] [Related]
38. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience.
Belge C; Delcroix M
Ther Adv Respir Dis; 2019; 13():1753466618823440. PubMed ID: 30736726
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous determination of macitentan and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry.
Yu L; Zhou Y; He X; Li H; Chen H; Li W
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Oct; 1002():358-63. PubMed ID: 26363370
[TBL] [Abstract][Full Text] [Related]
40. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
Gatfield J; Mueller Grandjean C; Sasse T; Clozel M; Nayler O
PLoS One; 2012; 7(10):e47662. PubMed ID: 23077657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
